Stay updated with breaking news from True Human. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQNatrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic DiseaseAUSTIN, Texas, Jan. 26, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASD...
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After StrokeAUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced
(1) XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer AUSTIN, Texas, April 19, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the FDA has granted permission to commence clinical trials with its novel drug candidate for treating patients with pancreatic cancer. From 1992 to 2018 the death rate from pancreatic cancer steadily increased in the USA. It is now predicted that pancreatic cancer will claim 48,220 lives and be the 3 rd leading cause of cancer death in the USA in 2021 (National Cancer Institute's Surveillance, Epidemiology...
XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain January 21, 2021 08:15 ET | Source: XBiotech Inc. XBiotech Inc. Austin, Texas, UNITED STATES AUSTIN, Texas, Jan. 21, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announces that its COVID-19 candidate True Human™ antibody therapy may also be used for trea...
Investegate announcements from XBiotech Inc., XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain